A lthough drug-drug interactions are known to change dose-response relationships so that coadministered agents become less effective or more toxic, drug-drug interactions are not always systematically investigated. Examining 76 of 2841 package inserts chosen randomly from the 1996 Physicians' Desk Reference, Spyker et al 1 stated that less than 30% provided information about metabolic routes of elimination, and less than 50% reported dosage adjustment information based on drug interaction data. With sometimes less than optimal information available in product labeling, coupled with a steady increase in the number of prescription medications prescribed to a single patient, 2 important metabolic drug-drug interactions can go undetected until serious consequences are reported. For example, inhibition of terfenadine metabolism by ketoconazole, erythromycin, and other drugs, which is associated with the serious adverse (cimetidine, digoxin, or warfarin) 
This report investigates the quality and quantity of drug-drug interaction studies in recent new drug applications (NDAs). Eighty-nine studies contained in 14 NDAs submitted between December 1995 and November 1996 to the U.S. Food and Drug Administration (FDA) were reviewed. The results indicated that the median number of clinical drug-drug interaction studies per NDA was 6, almost double that of a 1994-1995 survey. In vitro metabolism data were present in 70% of the submissions. More than 50% of the submissions contained interaction studies using a battery of drugs (cimetidine, digoxin, or warfarin) without optimal use of the in vitro
Further investigations into the mechanism of these interactions [4] [5] [6] and reporting of additional cases prompted changes in approved labeling and public warnings, both for the interacting drugs and for terfenadine and other nonsedating antihistamines such as astemizole. 7 These public statements have been critical. A recent survey using 1993 as a baseline indicated that issuance of warning letters and revision of labeling for ketoconazole, erythromycin, and terfenadine reduced significantly their rate of coprescription. 8 Because the initial finding for terfenadine was unexpected, these data emphasize the importance of thorough mechanistic assessment of drug-drug interaction studies during the investigational period of drug development. In the past, drug-drug interaction studies tended to be performed more empirically, where the impact of an investigational agent on the pharmacokinetics of a standard battery of drugs (e.g., digoxin, warfarin, theophylline, propranolol) was assessed. With a better understanding of the mechanistic basis for metabolic drug-drug interactions involving P450 enzymes, coupled with an awareness of the pharmacokinetic and pharmacodynamic profile of an investigational agent, better approaches are now available to assess drug-drug interactions. Significant advances in in vitro methods allow the exploration of potential metabolic drug interactions early in drug development and may obviate the need for further investigations. 9 This approach, coupled with further systematic evaluations of metabolic and other drugdrug interactions in the clinic when necessary, can promote the availability of useful and perhaps even life-saving information in product labeling. In certain instances, drug-drug interaction information can be used to therapeutic advantage as well as to provide warnings. For example, coadministration of single doses of ritonavir with saquinavir increases the oral bioavailability of the latter by more than 50-fold, 10 an observation that is used to allow optimal doses of the two agents when used in combination. [11] [12] [13] [14] The availability of new methods (e.g., in vitro methods using human tissues) to assess more efficiently potential metabolic drug-drug interactions, the increasing awareness of the importance of certain drug-drug interactions, and the rise in polypharmacy argue for a rational, coordinated, comprehensive approach to assess metabolic and other drug-drug interactions during the drug development process. To provide an understanding of current practices, we provide information in this report about the design and analysis of drug-drug interaction studies contained in recent new drug application (NDA) submissions. The information is provided in the expectation that an understanding of current approaches-what has worked and what has not-will help lead to improvements, based on a better scientific understanding, in the way future drug-drug interaction studies can be designed and executed.
METHODS
The report is based on clinical and other drug-drug interaction studies submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA) in NDAs for 14 new molecular entities (NMEs) intended for oral administration in immediate-release formulations ( Table I ). The NDAs for these NMEs were filed between December 1995 and November 1996, and the drug-drug interaction information in the 14 NDAs was reviewed by the Office of Clinical Pharmacology and Biopharmaceutics in the center between September 1996 and May 1997. Other NDAs that contained non-NMEs or other routes of administration, although also reviewed during this period, were not included in this evaluation. Data collection focused on results from in vitro metabolism/interaction studies in human tissues, clinical mass balance studies, and clinical interaction studies between the investigational NME and the previously approved interacting drug (ID). For the clinical studies, the following study elements were analyzed: (1) dosing regimens and study designs, (2) numbers and types of subjects, (3) dose sizes, (4) interacting drugs, (5) end points, (6) data analyses and interpretations, and (7) conclusions and proposed labeling. Data from studies to evaluate drug-food, drug-antacid, and drug-milk interactions were not included.
RESULTS
A total of 89 clinical studies investigating drug-drug interactions were contained in the 14 NDAs. The median number of studies per NDA was 6 (range: 0 to 13), with 4 (range: 0 to 13) evaluating the effect of the NME on ID and 2 (range: 0 to 9) evaluating the effect of ID on the NME (Table I) .
Dosing regimen and study design. Dosing regimens could be one of three combinations of single-dose (SD) and multiple-dose (MD) regimens for the NME and ID: (1) SD/SD, (2) MD/SD, and (3) MD/MD. The MD/MD was most often used (48%), followed by MD/SD (35%) and SD/SD (17%). For study design, the studies usually were conducted as a one-way crossover (fixedsequence) design (70%) and less often as a randomized crossover (21%) or parallel group design (8%). Combining both dosage regimen and study design factors, the most frequently used design was MD/MD (36%) in a one-way crossover design. The effect of timing on the end points of interest of ID or NME (i.e., concurrent administration vs. administration separated by 1, 2, 3, or more hours) was assessed in only one study.
Number and type of subjects. Most of the 89 studies used healthy volunteers (75%), with the remaining using patients for whom the NME was intended. The median number of subjects per study was 12 and was also 12 for randomized and one-way crossover designs, while the median number was 20 for the parallel group design study. Overall, female subjects were recruited in one-third of the studies. When patients were studied, the most frequently used design was the MD/MD combination. NME dose size. Proposed labeling for the 14 NMEs recommended either a single-dose size or multipledose sizes (e.g., high, medium, and low). The following four dose size selections for the NMEs were noted. (1) When only a single dose was recommended in the labeling and the effect of ID on the NME was studied, 80% of the studies used the dose that was proposed in the NME labeling, and the remainder used either a lower dose (15%) or a higher dose (5%). (2) When the proposed labeling recommended high, medium, and low doses and the effect of ID on NME was studied, the highest proposed NME dose was used in 28%, the intermediate dose was used in 39%, and the lowest dose was used in 33% of the studies. (3) When only a single dose was recommended in the labeling and the effect of the NME on ID was studied, 80% of the studies used the NME dose that was proposed in the labeling, and the remainder used either a lower dose (16%) or a higher dose (3%). (4) When the proposed labeling recommended high, medium, and low doses and the effect of NME on ID was studied, the highest proposed NME dose was used in 40%, the intermediate dose was used in 12%, and the lowest dose was used in 25% of the studies. In the remaining 23%, the dose of the NME selected for study was either lower (7%) than the lowest dose or higher than the highest dose (16%) proposed in the labeling. Overall, only 23% of the studies used the same NME dose when the NME was studied more than once. In 30% of the studies, differential effects of various dose sizes were explored, with the remainder of the studies using only one NME dose size.
Selection of interacting drugs (IDs).
In the 89 studies for the 14 NMEs, a total of 49 IDs were used, with 8 of these used in more than 2 studies (Table II) The sum of numbers (99) for ID on NME (37) and NME on ID (62) studies is larger than the total (89) because 10 of the 89 studies evaluated both ID on NME and NME on ID within one study.
on the NME was studied, while digoxin and warfarin were the most frequently used IDs when the effects of the NME on ID were studied. When the effect of ID on the NME was studied, prior in vitro data were available for 9 of 13 NMEs. When the effect of the NME on ID was studied, prior in vitro data were available for 6 of 13 NMEs. Sponsors appeared to have relied on in vitro metabolism/in vivo mass balance data more frequently (9/13, or 70% of submissions) in the design of clinical ID on NME studies than they did in the design of NME on ID studies (6/13, or 46% of submissions) (Table III) . Forty-six (ID on NME) and 61% (NME on ID) of the clinical studies appeared to have selected interacting drugs based on the possibility of coadministration, while 77% of the submissions studied the NME's effects on ID where ID was considered to be a narrow therapeutic range drug (Table III) . Overall, a combination of in vitro metabolism, in vitro interaction, and/or mass balance data was available and appeared to be useful in the design of clinical interaction studies.
Population pharmacokinetic analysis. In 21% of the submissions, the sponsor included interaction data obtained from clinical trials using population pharmacokinetic analysis.
End points. Ninety percent of the submissions used pharmacokinetic end points such as AUC, C max , C min , clearance, volume of distribution, and half-life, and 10% used pharmacodynamic end points such as prothrombin time and blood pressure to assess the presence or absence of a drug interaction.
Data analysis. All data were presented as mean and SD. When the number of subjects was greater than 6, sponsors tended to use the ANOVA to test the null hypothesis of no statistically significant interaction. In 80% of the submissions, p-values at an alpha level of 0.05 were used for determining the statistical significance. For studies in which an observed difference was statistically significant (p < 0.05), sponsors then used judgment to determine whether the observed difference, even though statistically significant, was clinically relevant. Thirty percent of the submissions determined the 90% confidence intervals (CI) of the mean ratios of key pharmacokinetic or pharmacodynamic parameters and compared the observed CI range with a specified equivalence interval, such as 80% to 125% or 50% to 200%, to determine whether the observed difference was clinically important. Eleven percent of the clinical studies investigated bidirectional interactions (ID on NME and NME on ID). Only an additional 10% of the studies (ID on NME or NME on ID) measured plasma levels of both interacting drugs.
Conclusion and proposed labeling. Sponsors concluded no clinically significant drug-drug interactions in 82% (73 of 89) of the studies. In certain studies, differences between the p-value (for the null hypothesis of no drug interactions) and confidence interval analyses were observed. An example is provided in Table IV . In this case, although one of the p-values showed significant difference due to a small intrasubject variation, the difference was not considered clinically DRUG DEVELOPMENT The ratios of the PK end point of the drug, when given together with the interacting drug and when given alone, were calculated. significant, as provided by the small 90% CI. The results from the CI analysis were used for the labeling language.
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DISCUSSION
Review of recent NDA submissions between 1995 and 1996 for orally administered NMEs indicated that a high percentage (93%) contained clinical drug-drug interaction studies investigating the effect of the NME on ID, with 79% also investigating the effect of ID on the NME. The median number of studies per NDA was 6, almost double that of our 1994-1995 review. 15 When the effect of ID on the NME was studied, the choice of ID was frequently (70%) based on knowledge of in vitro metabolic pathways. This again shows an improvement over the prior year. For submissions between 1994 and 1995, only 19% had in vitro metabolism information. 15 However, the in vitro information did not appear to be optimally used in current submissions. For example, cimetidine was used for studying metabolic drugdrug interactions in half of the submissions. In more than 50% of these instances, CYP3A was identified as the main enzyme responsible for NME's metabolism. Because cimetidine is a nonspecific cytochrome P450 inhibitor that also inhibits renal tubular secretion, its value in assessing interactions based on CYP3A metabolism is limited. In many instances, the choice of ID when assessing the effect of the NME on ID was based primarily on possible clinical coprescription and the therapeutic ranges of the interacting drugs. For example, in AIDS therapy, combinations of the NME with other protease inhibitors or reverse transcriptase inhibitors were often studied. Narrow therapeutic range agents such as digoxin and warfarin were studied in half of the submissions, irrespective of likeliness of coadministration. Although these are reasonable approaches, the number of studies was at times unnecessarily high. We suggest that whether a clinical metabolic drug-drug interaction is needed and, if needed, what interacting drugs to study should be based on prior information that includes in vitro metabolism/interaction and in vivo mass balance data. example, with a two-level approach (see Figure 1) , the number of clinical metabolic drug-drug interaction studies may be reduced. When the most potent inhibitor/inducer or the most sensitive/specific substrates are used in the first-level testing and the results are negative, subsequent studies (second level) may not be needed. Figure 1 illustrates how such decisions can be made.
Recently, postmarketing reports have found unexpected, serious adverse events and deaths when the calcium channel blocker mibefradil was given together with simvastatin or warfarin 16 in the presence of other therapies and preexisting disease states. These interactions appear to be based on the strong inhibition of CYP3A metabolism for simvastatin and possibly also CYP2C9 for warfarin by mibefradil. In addition, mibefradil appeared to affect the p-glycoprotein transporter. 17 Although limited in vitro data are available for the effects of mibefradil on metabolic pathways, these findings point to the importance of studying in vitro effects early in drug development and the importance of selecting the appropriate drug for subsequent clinical drug-drug interaction studies. This approach may have helped anticipate the serious adverse events uncovered when mibefradil was coadministered with other commonly coprescribed agents, 18-19 which eventually contributed to its market withdrawal.
Many factors in the study design can affect the outcome and interpretation of studies. Table V lists some important factors to consider. 20 The dose size, dosing regimen, and dosing duration are all important considerations because these factors determine the exposure levels of the interacting drugs. In 82% of the studies submitted, the sponsors concluded no clinically significant drug interactions. Study design is key to document this conclusion. For example, when studying the effect of NME on ID, 80% of the studies appropriately used the proposed dose or the highest dose if several doses were being proposed. There were, however, situations when the lowest NME dose or doses below the proposed dose range were used in some but not all of the studies from the same sponsor. In these cases, extrapolation of the negative findings to the higher dose situations would be difficult.
The current investigation showed that a variety of study designs were employed in the evaluation of drug-drug interactions. The multiple-dose/multipledose combination of the interacting drugs appeared to be the most often employed and, if the appropriate dose size and dosing duration were also used, may represent the most optimal study design. There are, however, other designs that are suitable as long as the exposure levels for both interacting drugs mimic what would be observed in the clinical setting. Recent information by Hsu et al 10, 21 showed that the interaction was much greater when a single dose of ritonavir was given in combination with saquinavir compared to when multiple doses of ritonavir were given. Because ritonavir induces its own metabolism, the multiple-dose administration produced lower exposure and therefore was not able to inhibit the metabolism of saquinavir to the same extent as the single-dose administration. This example points to the importance of using multiple-dose administration when single-dose pharmacokinetic data do not predict that of multiple-dose data. Another comparative study by Kurtz et al 22 demonstrated how the study design can critically affect the study outcome when metabolites are also inhibitors and also exhibit nonlinear pharmacokinetics. In this study, single-dose administration of sertraline showed no inhibition of the metabolism of desipramine and imipramine, while multiple doses of sertraline showed significant inhibition (> 70% increase in the AUC values). Not only had sertraline accumulated (two times) after multiple doses, but its desmethyl metabolite, which has a longer t 1/2 and also interacts with both desipramine and imipramine, also DRUG DEVELOPMENT accumulated significantly (five to nine times) after multiple doses. The study duration is an additional critical factor to consider when evaluating drug-drug interations due to enzyme inductions. In this current evaluation, the sponsors used relevant, multiple doses of both rifampin and rifabutin to study enzyme induction.
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Our investigation of recent submissions also revealed that the one-way crossover design (or fixed sequence) appeared to be the method of choice. Seventy percent of the studies used this design. However, most of the studies only looked at the steady-state add-on phase, and only 3% of the studies also investigated the washout phase after the inducer/inhibitor had been discontinued, an important phase to study, especially when enzyme induction may be the mechanism of interaction. The importance of studying the washout phase or reporting this information in the labeling was further highlighted when serious adverse events (including one death) were reported in patients who were put on dihydropyridine calcium channel blockers immediately after mibefradil was discontinued without the proper washout period. 23 One other important factor not routinely assessed in NDA studies is the timing and order of the coadministration of the interacting drugs. Depending on the time elapsed between the administration of the interacting drug and the substrate, the magnitude of changes in the pharmacokinetic parameters of the substrate may vary. For example, one recent study showed that the consumption of double-strength grapefruit juice at the time of (and also at 2 hours after) the administration of lovastatin increased the AUC values of lovastatin and its acid metabolite to 15-and 5-fold, respectively. 24 In contrast, the corresponding AUC ratios were less pronounced, 2-and 1.6-fold, respectively, when regularstrength grapefruit juice was ingested 12 hours before lovastatin was taken. 25 To provide proper labeling information, various possibilities of coadministration should be considered.
Review of the current submissions indicated that results of the p-value analysis were often insufficient to make a decision on the clinical significance of the interactions. With a median number of 12 subjects used in typical drug interaction studies, the variability of the parameters may preclude the detection of a meaningful difference. The confidence interval (CI) approach has not gained widespread use in the reporting of results from clinical efficacy trials, although it has been advocated as an appropriate measure. [26] [27] Recently, the CI approach has been used increasingly in the analysis of drug-drug interactions. [28] [29] [30] Thirty percent of the recent submissions estimated 90% CI and compared these values with the conventional equivalence range (80%-125%) to determine clinical significance. When the 90% CI was within the equivalence boundary, the sponsors declared no drug interactions. Ten percent of the studies also applied the CI approach to PD measurements. In two submissions, a no-effect boundary of 50% to 200% was selected, and the 90% CI values were compared with this boundary to determine the clinical significance. Evaluation of drug interactions may be viewed as assessing therapeutic equivalence. A measure of a CI of the ratios of key pharmacokinetic parameters with or without the interacting drugs can be estimated and compared to a clinical "no-effect boundary." [31] [32] If the CI falls within the no-effect boundary, no dosage adjustment is needed. As illustrated in Figure 2 , the no-effect boundary is constructed based on a balance of the therapeutic and adverse response at a given labeled dose or concentration. As such, this boundary does not need to be symmetrical around the mean.
When appropriately conducted, 33 population pharmacokinetic and pharmacodynamic analysis can be a powerful tool in the evaluation of drug-drug interactions. Recent examples have shown its use in uncovering unexpected drug-drug interactions. An unexpected decrease in the drug levels in patients when rifampin was coadministered prompted more investigation that resulted in labeling changes for a drug that was thought to be not metabolized. 20 In another study by Erickson et al, 34 additional drug-drug interaction studies uncovered bidirectional drug interactions when the population pharmacokinetic analysis did not demonstrate drug interactions between nevirapine and ketoconazole, as would be predicted from in vitro data. In this case, ketoconazole levels were reduced in the presence of nevirapine, which appeared to induce both CYP3A4 and CYP2B6. 35 The finding may partly explain its lower inhibition effects of ketoconazole in vivo. Our evaluation of the current submissions indicated that 21% of submissions applied the population PK analysis in the evaluation of drug interactions.
In summary, this survey indicated that drug-drug interactions have been evaluated in most of the NDA submissions using both in vitro and in vivo methodologies. The proper use of the in vitro metabolism, interaction, and the in vivo disposition data should provide more focused and perhaps fewer clinical metabolic drug-drug interaction studies and should result in more informative labeling and better patient care. An FDA guidance for industry 32 dealing with the design, analysis, and labeling language of in vivo human drug-drug interaction has been developed to assist sponsors and agency reviewers with these issues.
